menu
    • menu
    [{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu)-lilotomab satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Alpha37","moa":"CD37","graph1":"Oncology","graph2":"Preclinical","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu)-lilotomab satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu) lilotomab satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Lutetium (177Lu) lilotomab satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"177Lu lilotomab satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"ICON Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Nanovector \/ ICON Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ ICON Clinical Research"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase I","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu-DOTA-NNV003","moa":"CD37","graph1":"Oncology","graph2":"Preclinical","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"177Lu Lilotomab Satetraxetan","moa":"CD37","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Nordic Nanovector \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ Not Applicable"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"APIM Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Merger","leadProduct":"Sodium Deoxycholate","moa":"PCNA\/APIM PPI","graph1":"Oncology","graph2":"Phase II","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Nordic Nanovector \/ APIM Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"Nordic Nanovector \/ APIM Therapeutics"},{"orgOrder":0,"company":"Nordic Nanovector","sponsor":"Thor Medical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Radioimmunoconjugate-based Therapy","moa":"","graph1":"Oncology","graph2":"Undisclosed","graph3":"Nordic Nanovector","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nordic Nanovector \/ Nordic Nanovector","highestDevelopmentStatusID":"1","companyTruncated":"Nordic Nanovector \/ Nordic Nanovector"}]

    Find Clinical Drug Pipeline Developments & Deals by Nordic Nanovector

    Menu

    Nordic Nanovector

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Radioimmunoconjugate-based Therapy

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Recipient : Thor Medical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Nordic Nanovector Announces Agreement to Acquire Thor Medical, an Emerging Producer of Alpha-emitters for Radi...

                            Details : Through the acquisition, Nordic Nanovector gains access to highly promising new technology that enables the development and production of radionuclides for radioimmunoconjugate-based approaches to cancer treatment.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            June 06, 2023

                            Lead Product(s) : Radioimmunoconjugate-based Therapy

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Recipient : Thor Medical

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sodium Deoxycholate

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : APIM Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Nordic Nanovector and APIM Therapeutics Announce Merger Agreement

                            Details : ATX-101 is a first-in-class peptide targeting PCNA (Proliferating Cell Nuclear Antigen), a master regulator of cellular responses to stress and in tumour cell evasion from therapy. ATX-101 is currently being evaluated in platinum-sensitive ovarian cancer...

                            Brand Name : ATX-101

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            November 09, 2022

                            Lead Product(s) : Sodium Deoxycholate

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : APIM Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin in 3L R and R Follicular Lymphom...

                            Details : Betalutin (177Lu lilotomab satetraxetan), is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) for the treatment of Hodgkin B-cell lymphoma.

                            Brand Name : Betalutin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            July 05, 2022

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan,Lilotomab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector to Seek Regulatory Feedback Following its Preliminary Review and Independent Data Evaluation...

                            Details : Betalutin® (177Lu Lilotomab Satetraxetan), showed signs of efficacy in this frail, elderly and difficult-to-treat patient population, the independent expert panel reported that the efficacy data are less promising than the data reported from the Phase 2...

                            Brand Name : Betalutin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 21, 2022

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan,Lilotomab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b...

                            Details : The primary objective of the PARADIGME trials is to determine the effectiveness of Betalutin (177Lu Lilotomab Satetraxetan), a novel single-dose radioimmunotherapy that targets CD37, an antigen found on the surface of tumour cells of Follicular Lymphoma.

                            Brand Name : Betalutin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 02, 2022

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu-DOTA-NNV003,Olaparib

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector: New Publication Highlights Synergistic Potential of CD37-targeted Radioimmunoconjugate Huma...

                            Details : Humalutin® (177Lu-DOTA-NNV003), acts by inducing potentially cytotoxic DNA breaks in the NHL cells, sensitising these cells to olaparib, which prevents repair of DNA breaks by blocking activity of DNA repair enzymes poly (ADP ribose) polymerase 1 and 2 ...

                            Brand Name : Humalutin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 03, 2022

                            Lead Product(s) : 177Lu-DOTA-NNV003,Olaparib

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector Provides update on PARADIGME, its Phase 2b Pivotal Trial with Betalutin® in R/R Follicular ...

                            Details : 106 patients has been enrolled for PARADIGME, ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) for the treatment of anti-CD20 refractory follicular lymphoma.PARADIGME data to be reported in second half of 2022.

                            Brand Name : Betalutin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            January 07, 2022

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector to Present at 3rd Targeted Radiopharmaceutical Summit 2021

                            Details : Betalutin® (177Lu-lilotomab satetraxetan), an anti-CD37 beta-emitting radioimmuno conjugate has shown an encouraging efficacy and safety profile in 3rd line NHL patients who are refractory to anti-CD20-based treatments.

                            Brand Name : Betalutin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 07, 2021

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : ICON Clinical Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector Sees Significant Improvement in Patient Recruitment Rate in PARADIGME

                            Details : Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).

                            Brand Name : Betalutin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            February 18, 2021

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : ICON Clinical Research

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Nordic Nanovector

                            Norway arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nordic Nanovector Completes Patient Enrolment into Phase 1 trial of Betalutin® in Diffuse Large B Cell Lympho...

                            Details : Nordic Nanovector has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell tran...

                            Brand Name : Betalutin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 01, 2020

                            Lead Product(s) : 177Lu Lilotomab Satetraxetan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth